Approximately 80% of low-grade gliomas harbor recurrent mutations in the isocitrate dehydrogenase genes 1 and 2 (commonly referred to as IDH1 and IDH2, respectively) [28,72]. This evidence concerns the gene IDH1 and central nervous system cancer.